SCHEMBL735804

SCHEMBL735804

Nc1ccc2nn[nH]c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.48
MAPT P10636 12/20 0.47
KDM4E B2RXH2 10/20 0.47
RAD52 P43351 1/20 0.47
MEN1 O00255 10/20 0.44
KMT2A Q03164 10/20 0.44
RXFP1 Q9HBX9 2/20 0.44
CACNA1B Q00975 1/20 0.44
APBA1 Q02410 1/20 0.44
PKM P14618 4/20 0.44
HTT P42858 3/20 0.44
DYRK1A Q13627 1/20 0.43
GAA P10253 7/20 0.43
ALDH1A1 P00352 6/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
RAB9A P51151 5/20 0.43
NPC1 O15118 4/20 0.43
GLA P06280 3/20 0.43
RECQL P46063 2/20 0.43
GFER P55789 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetamide SCHEMBL7680194 0.83 MAPT (0.41) PRKCIMAPTKDM4ERAD52MEN1
Trifluoroacetic Acid SCHEMBL4108467 0.83 MAPT (0.41) PRKCIMAPTKDM4ERAD52MEN1
SCHEMBL111984 0.83 DYRK1A (0.48) PRKCIMAPTKDM4ERAD52MEN1
Tert-Butyl Formate SCHEMBL28826667 0.81 TDP1 (0.37) PRKCIMAPTKDM4ERAD52MEN1
SCHEMBL8421908 0.81 DYRK1A (0.47) PRKCIMAPTKDM4ERAD52MEN1
Fluoride SCHEMBL31379737 0.81 DYRK1A (0.47) PRKCIMAPTKDM4ERAD52MEN1
Hydrochloric Acid SCHEMBL2493619 0.81 DYRK1A (0.47) PRKCIMAPTKDM4ERAD52MEN1
Hydrochloric Acid SCHEMBL10929282 0.81 DYRK1A (0.47) PRKCIMAPTKDM4ERAD52MEN1
SCHEMBL12871076 0.74
SCHEMBL2611832 0.74 KMT2A (0.43) MAPTKDM4EKMT2AHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110713868-A Post etch residue cleaning solution capable of removing titanium nitride 巴斯夫欧洲公司 2020-01-21 CN claimed
CN-101686979-A The urea modulators that the heteroaryl of fatty acid amide hydrolase replaces JANSSEN PHARMACEUTICA NV 2010-03-31 CN claimed
EP-2164493-A2 HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE Janssen Pharmaceutica, N.V. (BE) 2010-03-24 EP claimed
US-20090062294-A1 HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2009-03-05 US claimed
WO-2008153752-A2 HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-12-18 WO claimed
EP-0851282-B1 Processing of a light-sensitive silver halide photographic material AGFA GEVAERT (BE) 2003-04-16 EP claimed
US-5912108-A FORMING IMAGES BY EXPOSURE TO LIGHT ON SUPPORTS AGFA-GEVAERT, N.V. (BE) 1999-06-15 US claimed
EP-0851282-A1 Processing of a light-sensitive silver halide photographic material AGFA-GEVAERT N.V. (BE) 1998-07-01 EP claimed
US-20250197399-A1 COMPOUNDS, COMPOSITIONS, AND METHODS TENVIE THERAPEUTICS, INC. 2025-06-19 US disclosed
EP-4499626-A1 COMPOUNDS, COMPOSITIONS, AND METHODS Nico Therapeutics, Inc. (US) 2025-02-05 EP disclosed
CN-119233972-A Compounds, compositions, and methods 尼科治疗有限公司 2024-12-31 CN disclosed
WO-2023192390-A1 COMPOUNDS, COMPOSITIONS, AND METHODS DENALI THERAPEUTICS INC. (US) 2023-10-05 WO disclosed
US-11414410-B2 Inhibitors of protein kinases ALEXION PHARMACEUTICALS, INC. (US) 2022-08-16 US disclosed
US-11299480-B2 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors UNIVERSITY OF HAWAII (US) 2022-04-12 US disclosed
WO-2006062982-A2 UREA INHIBITORS OF MAP KINASES LOCUS PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed
EP-1519235-A2 Linked dihydrazone-based charge transport compounds Samsung Electronics Co., Ltd. (KR) 2005-03-30 EP disclosed
US-20050058916-A1 Linked dihydrazone-based charge transport compounds S-PRINTING SOLUTION CO., LTD. (KR) 2005-03-17 US disclosed
EP-0851282-B1 Processing of a light-sensitive silver halide photographic material AGFA GEVAERT (BE) 2003-04-16 EP disclosed
US-5912108-A FORMING IMAGES BY EXPOSURE TO LIGHT ON SUPPORTS AGFA-GEVAERT, N.V. (BE) 1999-06-15 US disclosed
EP-0851282-A1 Processing of a light-sensitive silver halide photographic material AGFA-GEVAERT N.V. (BE) 1998-07-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11299480-B2 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors STAT3, JAK2, STAT5A PRKCI 397/4885MAPT 3464/4885KDM4E 2607/4885
US-20090062294-A1 HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, GPR119 PRKCI 1870/4885MAPT 1808/4885KDM4E 950/4885
US-11414410-B2 Inhibitors of protein kinases MAP3K1, MAP3K20, MAP3K2 PRKCI 77/4885MAPT 2325/4885KDM4E 1016/4885
US-20250197399-A1 COMPOUNDS, COMPOSITIONS, AND METHODS NLRP3, NLRP1, NOD1 PRKCI 2951/4885MAPT 3816/4885KDM4E 3822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.